Evidence map›Paper›PMID 39158279›Full record

ArticleAntimicrobial agents and chemotherapy2024

Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-β-lactamase-producing carbapenem-resistant gram-negative bacilli.

Lili Tao, Ashley Dahlquist, Harley Harris, Emily Jacobs, Eric Wenzler, Patricia J Simner, Romney Humphries

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline for antimicrobial treatment of multidrug-resistant Gram-negative infections: practice recommendations of the Brazilian Society of Infectious Diseases.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Guideline
  2. In vitro activity of β-lactamase inhibitors avibactam, relebactam and vaborbactam in combination with aztreonam against metallo-β-lactamase producing Escherichia coli clinical isolates.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  3. Optimizing target inactivation to treat multidrug-resistantAntimicrobial agents and chemotherapy · 2026
    Article
  4. Article
  5. Infection and drug resistance · 2026
    Review
  6. Review
  7. Microbiology spectrum · 2025
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lili TaoDepartment of Pathology, Microbiology and Immunology, Division of Laboratory Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0002-9682-3911
Ashley DahlquistCollege of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA.
Harley HarrisDepartment of Pathology, Division of Medical Microbiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-6314-6854
Emily JacobsDepartment of Pathology, Division of Medical Microbiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Eric WenzlerCollege of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA.
Patricia J SimnerDepartment of Pathology, Division of Medical Microbiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-6134-151X
Romney HumphriesDepartment of Pathology, Microbiology and Immunology, Division of Laboratory Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0002-6568-156X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment options for carbapenem-resistant gram-negative bacilli (CR-GNB), especially metallo-β-lactamase (MBL)-producing CR-GNB, are limited. Aztreonam (ATM) in combination with avibactam (AVI) has shown potential for treating MBL-producing carbapenem-resistant Enterobacterales (CREs) and

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsAztreonambeta-Lactamase Inhibitorsbeta-LactamasesBoronic AcidsMicrobial Sensitivity TestsCarbapenemsGram-Negative BacteriaHumansStenotrophomonas maltophiliaTazobactamAnti-Bacterial AgentsavibactamAzabicyclo CompoundsAztreonambeta-Lactamase Inhibitorsbeta-LactamasesBoronic AcidsCarbapenemsrelebactamTazobactamvaborbactamantibiotic resistanceantimicrobial combinationsEnterobacteriaceaegram-negative bacteriaStenotrophomonasβ-lactamases

Identifiers

PMID39158279
PMCPMC11459955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.